ArticleThe Journal of investigative dermatology2018
Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A.
Article in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therapeutic Approaches.International journal of molecular sciences · 2023Trial
- Restoration of Keratinocyte Homeostasis Drives Resolution of Skin Inflammation.bioRxiv : the preprint server for biology · 2026Article
- G-CSF Mediates Increased Renal Neutrophils and Kidney Damage in a Psoriasis Mouse Model.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Bridging worlds: a narrative review of IL-17 at the crossroads of inflammation and thrombosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Enhancing the treatment potential of IL-17 antagonism in lupus nephritis: finding the right partner.Frontiers in immunology · 2025Review
- Overall hemostatic potential as a marker of subclinical hypercoagulability in treated psoriasis patients.Frontiers in medicine · 2025Article
- Suppression of TCF4 promotes a ZC3H12A-mediated self-sustaining inflammatory feedback cycle involving IL-17RA/IL-17RE epidermal signaling.JCI insight · 2024Article
- A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State.Dermatology and therapy · 2024Article
- RNA-Based Antipsoriatic Gene Therapy: An Updated Review Focusing on Evidence from Animal Models.Drug design, development and therapy · 2024Review
- Mouse Models of Psoriasis: A Comprehensive Review.The Journal of investigative dermatology · 2022Review
- Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis.Frontiers in immunology · 2022Review
- Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics.Current atherosclerosis reports · 2021Review
- The metabolism-modulating activity of IL-17 signaling in health and disease.The Journal of experimental medicine · 2021Review
- Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.Dermatology and therapy · 2021Review
- Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?International journal of molecular sciences · 2021Review
- Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19.Journal of inflammation research · 2021Review
- Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk.Frontiers in immunology · 2021Review
- The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis.Frontiers in medicine · 2021Review
- The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Psoriasis patients experience chronic systemic skin inflammation and develop cardiovascular comorbidities that shorten their lifespan. Whether cardiovascular disease is improved by treatment with current biologics that target disease-specific pathways is unclear. KC-Tie2 mice develop psoriasiform skin inflammation with increases in IL-23 and IL-17A and proinflammatory monocytosis and neutrophilia that precedes development of carotid artery thrombus formation. To examine whether targeted blockade of IL-23 or IL-17A in KC-Tie2 psoriasis mice improves cardiovascular outcomes, mice were treated systemically for 6 weeks with antibodies targeting IL-17A, IL-17RA, IL-12/23p40, or IL-23p19. Skin inflammation; thrombosis clotting times; and percentage of splenic monocytes, neutrophils, and CD4 T cells were examined. Skin inflammation significantly improved in KC-Tie2 mice treated with each of the antibodies targeting IL-23, IL-17A, or IL-17RA, consistent with clinical efficacy observed in psoriasis patients. The time to occlusive thrombus formation lengthened in these mice and correlated with attenuated acanthosis. This decrease in skin inflammation paralleled decreases in splenic neutrophils (CD11b
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.